

EXPRESS MAIL LABEL NO.: EV518891071

PATENT

Attorney Docket No. 26050-712.201

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application

Inventor(s): WANG, Caili et al.

Application No.: 10/033,399

Filed: November 2, 2001

Title: ADAPTED-DIRECTED DISPLAY
SYSTEMS

PATENT APPLICATION

Art Unit: 1636

Examiner: Gerald G. Leffers, Jr., Ph.D.

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §1.97

Sir:

Applicants hereby submit a Supplemental Information Disclosure Statement along with attached form(s) PTO/SB/08. A copy of each listed publication except the U.S. patents is being submitted herewith, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached form(s) PTO/SB/08 in accordance with MPEP §609.

Applicants reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because:
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; **or**
- ☒ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ Copies of each of the references listed on the attached Form PTO/SB/08 are enclosed herewith except the U.S. patents.
- ☒ Copies of references listed on the attached Form PTO/SB/08 are enclosed herewith EXCEPT THAT:
- ☐ In view of the voluminous nature of references, and the likelihood that these references are available to the Examiner in the file history of the parent application (Serial No. _____), copies are not enclosed herewith.
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

- ☐ In view of the voluminous nature of references, and the likelihood that these references are available to the Examiner in the file history of the parent application (Serial No. _____), copies are not enclosed herewith.
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
- ☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).
- ☒ There are no listed references which are not in the English language.
- ☐ The relevance of those listed references which are not in the English language is as follows:
- ☐ Attached are copies of search report(s) from corresponding patent application(s), submitted in accordance with MPEP 609 D in support of the attached certification under 37 CFR 1.97(e)(1).
- ☐ Attached are the following non-published pending patent applications which may be deemed relevant.
- ☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No.26050-712.201).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: November 18, 2004

By: _____


Karen K. Wong, Ph.D., J.D.

650 Page Mill Road
Palo Alto, CA 94304-1050
(650) 849-3383
Customer No. 021971



Substitute for form 1449/PTO		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/033,399	
		Filing Date	November 2, 2001	
		First Named Inventor	WANG, Caili	
		Art Unit	1636	
		Examiner Name	Gerald G. Leffers, Jr., Ph.D.	
Sheet		of	Attorney Docket Number	26050-712.201

U.S. PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-5,770,442	06-23-1998	Cornell Research Foundation, Inc. and GenVec, Inc.	
	2	US-6,593,081	07-15-2003	Medical Research Council and Cambridge Antibody Technology Limited	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	BERGH, MICHEL L. E. et al. "Expression of the Saccharomyces cerevisiae Glycoprotein Invertase in Mouse Fibroblasts: Glycosylation, Secretion, and Enzymatic Activity. <i>Proc. Natl. Acad. Sci.</i> (1987) 84:(11) 3570-3574.	
	4	BIRD, PHILLIP et al. "Translocation in Yeast and Mammalian Cells: Not All Signal Sequences are Functionally Equivalent" <i>The Journal of Cell Biology</i> (1987) 105:(6) 2905-2914.	
	5	DANNER, STEFAN et al. "T7 Phage Display: A Novel Genetic Selection System for Cloning RNA-Binding Proteins from cDNA Libraries" <i>PNAS</i> (2001) 98:(23) 12954-12959.	
	6	DESAI, PRASHANT et al. "Incorporation of the Green Fluorescent Protein into the Herpes Simplex Virus Type 1 Capsid" <i>Journal of Virology</i> , (1998) 72:(9) 7563-7568.	
	7	DMITRIEV, IGOR P. et al. "Engineering of Adenovirus Vectors Containing Heterologous Peptide Sequences in the C Terminus of Capsid Protein IX" <i>Journal of Virology</i> , (2002) 76:(14) 6893-6899.	
	8	ERLWEIN, OTTO et al. "The Proline-Rich Region of the Ecotropic Moloney Murine Leukaemia Virus Envelope Protein Tolerates the Insertion of the Green Fluorescent Protein and Allows the Generation of Replication-Competent Virus" <i>Journal of General Virology</i> , (2003) 84:369-379.	
	9	FOX CHASE CANCER CENTER. "PGLS20 Vector: A Novel Dual Purpose Vector for Protein Expression in E. Coli and S. Cerevisiae" <i>Fox Chase Cancer Center</i> . 1-3.	
	10	HITZMAN, RONALD et al. "Secretion of Human Interferons By Yeast" <i>Science</i> (1983) 219:(4585) 620-625.	
	11	INVITROGEN. "pFliTrx Peptide Display Vector: A Cloning Vector for Studying Protein-Protein Interactions." Catalog no. V1126-01 Version D 010402 28-0144 <i>Invitrogen Life Technologies</i> . 1-25.	
	12	JABBAR, ABDUL et al. "Signal Processing, Glycosylation, and Secretion of Mutant Hemagglutinins of a Human Influenza Virus by Saccharomyces cerevisiae" <i>Mol. Cell Biol.</i> (1987) 7:(4) 1476-85.	



13	KABA, STEPHEN A. et al. "Baculovirus Surface Display of <i>Theileria parva</i> p67 Antigen Preserves the Conformation of Sporozoite-Neutralizing Epitopes" <i>Protein Engineering</i> , (2003) 16:(1) 73-78.
14	LI, LIN et al. "Functional Display of Foreign Protein on Surface of <i>Escherichia coli</i> Using N-Terminal Domain of Ice Nucleation Protein" <i>Biotechnology and Bioengineering</i> , (2004) 85:(2) 214-221.
15	NOVAGEN. "T7Select System Manual" <i>Novagen</i> , TB178 Rev.B 0203 United States & Canada 800-207-0144 1-23.
16	REN, Z.J. et al. "Phage Display of Intact Domains at High Copy Number: A System Based on SOC, the Small Outer Capsid Protein of Bacteriophage T4" <i>Protein Science</i> (1996) 5:1833-1843.
17	STERNBERG, NAT et al. "Display of Peptides and Proteins on the Surface of Bacteriophage λ " <i>Proc. Nat. Acad. Sci.</i> (1995) 92:1609-1613.
18	TALMADGE, KAREN et al. "Eukaryotic Signal Sequence Transports Insulin Antigen in <i>Escherichia Coli</i> ." <i>Proc. Natl. Acad. Sci.</i> (1980) 77(6):3369-3373.
19	WIEDMANN, M. et al. "Xenopus Oocytes Can Secrete Bacterial Beta-Lactamase" <i>Nature</i> (1984) 309(5969):637-639.
20	ZUCCONI, ADRIANA et al. "Selection of Ligands by Panning of Domain Libraries Displayed on Phage Lambda Reveals New Potential Partners of Synaptojanin 1" <i>Journal of Molecular Biology</i> (2001) 307:1329-1339.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.